SeaCrest Wealth Management LLC Trims Holdings in Organon & Co. (NYSE:OGN)

SeaCrest Wealth Management LLC decreased its position in shares of Organon & Co. (NYSE:OGN) by 33.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 10,851 shares of the company’s stock after selling 5,367 shares during the period. SeaCrest Wealth Management LLC’s holdings in Organon & Co. were worth $162,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Quad Cities Investment Group LLC lifted its position in Organon & Co. by 37.5% during the fourth quarter. Quad Cities Investment Group LLC now owns 15,211 shares of the company’s stock worth $227,000 after buying an additional 4,146 shares during the period. 180 Wealth Advisors LLC grew its holdings in Organon & Co. by 40.1% in the fourth quarter. 180 Wealth Advisors LLC now owns 58,293 shares of the company’s stock valued at $870,000 after purchasing an additional 16,697 shares during the period. Horizon Bancorp Inc. IN increased its position in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares during the last quarter. Wedmont Private Capital increased its holdings in shares of Organon & Co. by 453.4% during the 4th quarter. Wedmont Private Capital now owns 100,539 shares of the company’s stock worth $1,594,000 after buying an additional 82,372 shares during the last quarter. Finally, Clark & Stuart Inc purchased a new position in Organon & Co. in the fourth quarter valued at approximately $435,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of OGN opened at $15.77 on Friday. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76. The business’s 50 day moving average is $15.32 and its two-hundred day moving average is $18.22.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $0.78 earnings per share. Analysts forecast that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.10%. Organon & Co.’s dividend payout ratio (DPR) is 22.22%.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. currently has a consensus rating of “Hold” and a consensus target price of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.